The brand name company loses a large percent of market share as soon as a generic comes to market. A second generic coming to market doesn’t affect the brand name company much. My GUESS is Purdue will try to negotiate a payment from Elite to settle the suit. If Elite does not agree, Purdue continues the litigation for a few more months, then probably loses. Elite has to decide if getting their generic to market quicker is worth the price. This is just speculation on my part.
Market Data 
Markets 
AI
